Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis
Sarah P. Hammond(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Francisco M. Marty(Brigham and Women's Hospital), Phillip C. Camp(Brigham and Women's Hospital), Anne L. Fuhlbrigge(Brigham and Women's Hospital), Steven Gabardi(Brigham and Women's Hospital), Séverine Martin(Hôpital Pellegrin), Hilary J. Goldberg(Harvard University), Keri Roberts(NHS Blood and Transplant)
Cited by 38
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k